Elevated interleukin-6 in schizophrenia

Psychiatry Research

Volumn 87, Issue 2-3, 1999, Pages 129-136

  Van Kammen, Daniel P ^a,b   McAllister Sistilli, Cathy G ^a,b   Kelley, Mary E ^a   Gurklis, John A ^a,b   Yao, Jeffrey K ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

CSF; Interleukin 6; Schizophrenia; Serum

Indexed keywords

BENZATROPINE; HALOPERIDOL; INTERLEUKIN 6;

ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA;

EID: 0032697034     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(99)00053-0     Document Type: Article

References (51)

1. Akira S., Hirano T., Taga T., Kishimoto T. Biology of multifunctional cytokines: IL-6 and related molecules (IL1 and TNF). FASEB Journal. 4:1990;2860-2867.
2. Diagnostic and Statistical Manual of Mental Disorders. 3rd edn. 1987;American Psychiatric Press, Washington, DC.
3. Baker I., Masserano J., Wyatt R.J. Serum cytokine concentration in patients with schizophrenia. Schizophrenia Research. 20:1996;199-203.
4. Barak V., Barak Y., Levine J., Nisman B., Roisman I. Changes in interleukin-1 and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. Journal of Basic Clinical Physiology and Pharmacology. 6:1995;61-69.
5. De Vries H.E., Blom-Roosemalen M.C.M., Van Oosten M., De Boer A.G., Van Berkel T.J.C., Breimer D.D., Kuiper J. The influence of cytokines on the integrity of the blood-brain barrier in vitro. Journal of Neuroimmunology. 64:1996;37-43.
6. El-Mallakh R.S., Suddath R.L., Wyatt R.J. Interleukin-1α and interleukin-2 in cerebrospinal fluid of schizophrenia subjects. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 17:1993;383-391.
7. Frommberger U.H., Bauer J., Haselbauer P., Fraulin A., Riemann D., Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. European Archives of Psychiatry and Clinical Neuroscience. 247:1997;228-233.
8. Ganguli R., Rabin B.S., Belle S. Decreased interleukin 2 production in schizophrenic patients. Biological Psychiatry. 26:1989;424-427.
9. Ganguli R., Yang Z., Shurin G., Chengappa R.K.N., Brar J.S., Gubbi A.V., Rabin B.S. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Research. 51:1994;1-10.
10. 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proceedings of the National Academy of Sciences USA. 84:1987;7251-7255.
11. Grimaldi M., Meucci O., Scorziello A., Florio T., Ventra C., De Mercato R., Schettini G., Florio T. Interleukin 6 modulation of second messenger systems in anterior pituitary cells. Life Sciences. 51:1992;1243-1248.
12. Hama T., Miyamoto M., Tsukui H., Nishio C., Hatanaka H. Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats. Neuroscience Letters. 104:1989;340-344.
13. Hirano T., Akira S., Taga T., Kishimoto T. Biological and clinical aspects of interleukin-6. Immunology Today. 11:1996;443-449.
14. Hirano T., Matsuda T., Turner M., Miyasaka N., Buchan G., Tang B., Sato K., Shimizu M., Maini R., Feldmann M., Kishimoto T. European Journal of Immunology. 18:1988;1797-1801.
15. Hirohata S., Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with system lupus erythematosus and central nervous system involvement. Arthritis and Rheumatism. 33:1990;644-649.
16. Hirohata S., Tanimoto K., Ito K. Elevation of cerebrospinal fluid interleukin-6 activity in patients with vasculitides and central nervous system involvement. Clinical Immunology and Immunopathology. 66:1993;225-229.
17. Houssiau F.A., Devogelaer J.-P., Van Damme J., Nagant de Deuxchaisnes C., Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis and Rheumatism. 31:1988;784-788.
18. Katila H., Hurme M., Wahlbeck K., Appelberg B., Rimon R. Plasma and cerebrospinal fluid interleukin-1β and interleukin-6 in hospitalized schizophrenic patients. Neuropsychobiology. 30:1994;20-23.
19. Katila H., Appelberg B., Hurme M., Rimon R. Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophrenia Research. 12:1994;29-34.
20. Kishimoto T., Akira S., Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 258:1992;593-597.
21. Lemay L.G., Vander A.J., Kluger M.J. The effect of psychological stress on plasma interleukin-6 activity in rats. Physiology and Behavior. 47:1990;957-961.
22. Ledur A., Fitting C., David B., Hamberger C., Cavaillon J.-M. Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards. Journal of Immunological Methods. 186:1995;171-179.
23. Licinio J., Seibyl J.P., Altemus M., Charney D.S., Krystal J.H. Elevated CSF levels on interleukin-2 in neuroleptic-free schizophrenic patients. American Journal of Psychiatry. 150:1993;1408-1410.
24. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatrica Scandinavica. 89:1994;346-351.
25. Maes M., Meltzer H.Y., Buckley P., Bosmans E. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. European Archives of Psychiatry and Clinical Neuroscience. 244:1995;325-329.
26. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stablizers. Journal of Psychiatric Research. 29:1995;141-152.
27. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophrenia Research. 26:1997;221-225.
28. Maimone D., Gregory S., Arnason B.G.W., Reder A.T. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. Journal of Neuroimmunology. 32:1991;67-74.
29. Malek-Ahmadi P. Neuropsychiatric aspects of cytokines research: an overview. Neuroscience and Biobehavioral Reviews. 20:1996;359-365.
30. May L.T., Viguet H., Kenney J.S., Ida N., Allison A.C., Sehgal P.B. High levels of 'complexed' interleukin-6 in human blood. Journal of Biological Chemistry. 267:1992;19698-19704.
31. McAllister C.G., van Kammen D.P., Rehn T.J., Miller A.L., Gurklis J., Kelley M.E., Yao J., Peters J.L. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. American Journal of Psychiatry. 159:1995;1291-1297.
32. Naudin J., Mege J.L., Azorin J.M., Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophrenia Research. 20:1996;269-273.
33. Naudin J., Kapo C., Giusano B., Mege J.L., Azorin J.M. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophrenia Research. 26:1997;227-233.
34. Ndubuisi M.I., Patel K., Rayanade R.J., Mittelman A., May L.T., Seghal P.B. Distinct classes of chaperoned IL-6 in human blood: differential immunological and biological availability. Journal of Immunology. 160:1998;494-501.
35. Pollmächer T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. Journal of Clinical Psychopharmacology. 16:1996;403-409.
36. Pollmächer T., Hinze-Selch D., Fenzel T., Kraus T., Schuld A., Mullington J. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. American Journal of Psychiatry. 154:1997;1763-1765.
37. Ringheim G.E., Burgher K.L., Heroux J.A. Interleukin-6 mRNA expression by cortical neurons in culture: evidence for neuronal sources of interleukin-6 production in the brain. Journal of Neuroimmunology. 63:1995;113-123.
38. Satoh T., Nakamura S., Taga T., Matsuda T., Hirano T., Kishimoto T., Kaziro Y. Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Molecular and Cellular Biology. 8:1988;3546-3549.
39. Shintani F., Shigenobu K., Maruo N. et al. Serum interleukin-6 in schizophrenic patients. Life Sciences. 49:1991;661-664.
40. Spitzer R.L., Endicott J. The Schedule for Affective Disorders and Schizophrenia - Lifetime version. 3rd edn. 1979;New York State Psychiatric Institute, Biometrics Research, New York.
41. Spitzer R.L., Williams J.B.W., Gibbon M., First M.B. Structured Clinical Interview for DSM-III-R (SCID). 1989;New York State Psychiatric Institute, New York.
42. Stein T.P., Schluter M.D. Excretion of IL-6 by astronauts during spaceflight. American Journal of Physiology. 266:1994;E448-E452.
43. van Kammen D.P., Sternberg D.E. CSF studies in schizophrenia. Wood J.H. Neurobiology of Cerbrospinal Fluid, Vol. 1. 1980;719-742 Plenum Press, New York.
44. van Kammen D.P., Peters J.L., van Kammen W.B., Nugent A., Goetz K.L., Yao J., Linnoila M. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biological Psychiatry. 26:1989;176-188.
45. van Kammen D.P., Ågren H., Yao J.K., O'Connor D.T., Gurklis J.A., Peters J.L. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. American Journal of Psychiatry. 151:1994;379-384.
46. van Kammen, D.P., McAllister-Sistilli, C.G., Kelley, M.E., Gurklis, J.A., Yao, J.K., 1999. Methodological concerns in the study of the immune system in schizophrenia. In: Müller, N. (Ed.), Psychiatry, Psychoneuroimmunology, and Viruses. Springer Verlag, Vienna, New York, pp. 63-69.
47. Villemain F., Chatenoud L., Giullibert E., Pelicier Y., Bach J.F. Decreased production of interleukin-2 in schizophrenia. Annals of the New York Academy of Sciences. 496:1987;669-675.
48. Wei J., Xu H., Davies L., Hemmings G.P. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sciences. 52:1992;1953-1956.
49. Westerman J., Pabst R. Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? Immunology Today. 11:1990;406-410.
50. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.-F., Achong M.K. IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. Journal of Clinical Investigation. 101:1998;311-320.
51. Xu H.-M., Wei J., Hemmings G.P. Changes of plasma concentrations of interleukin-1α and interleukin-6 with neuroleptic treatment for schizophrenia. British Journal of Psychiatry. 164:1994;251-253.